First-line antihypertensive for a Black adult with stage 2 hypertension and no CKD?

For a Black adult with stage 2 hypertension and no CKD, start with a thiazide-type diuretic or calcium channel blocker (or both together, or paired with an ARB/RAS blocker per international guidance), and because this is stage 2 disease, initiate with two agents from different classes — ideally as a single-pill combination — rather than monotherapy.

First-line agent for Black adults without CKD

• JNC 8 recommends a thiazide-type diuretic or a calcium channel blocker as initial therapy for the general Black hypertensive population without CKD.
• For stage 2 hypertension specifically, the 2025 AHA/ACC guideline emphasizes starting with two first-line agents from different classes, ideally as a single-pill combination, to improve control and adherence, rather than designating a single preferred class by race.
• The 2025 AHA/ACC guideline does not include explicit race/ethnicity pharmacotherapy recommendations.

International and comparative guidance on race-specific therapy

• The 2020 International Society of Hypertension guidance recommends first-line therapy with a thiazide-like diuretic plus a calcium channel blocker, or a calcium channel blocker plus an ARB, for Black adults, preferring ARBs over ACE inhibitors because of higher angioedema risk in this population.
• NICE guidance recommends calcium channel blockers as first-line therapy for Black adults without type 2 diabetes.
• The 2024 European Society of Cardiology guideline attributes low-renin, salt-sensitive hypertension and elevated organ-damage risk to Black patients and recommends diuretics or calcium channel blockers, alone or with renin-angiotensin system blockers, noting reduced RAS-blocker efficacy in this group.

Combination strategy for stage 2 disease

• Multiple guidelines, including the 2018 ACC/AHA and related bodies, recommend starting stage 2 hypertension with two first-line agents from different classes rather than monotherapy.
• In a cohort of Black South African patients, appropriate combination therapy (commonly ACE inhibitor, CCB, and thiazide diuretic together) was used in most patients, consistent with international combination-therapy guidance, and a trial in Black sub-Saharan African patients found amlodipine plus hydrochlorothiazide or perindopril more effective than perindopril plus hydrochlorothiazide for reaching optimal BP.

Sources

• Bridging the Gap in Racial/Ethnic Disparities: Perspectives from the 2025 American Heart Association/American College of Cardiology High Blood Pressure Guideline — Current Hypertension Reports
• Blood pressure control in hypertensive patients attending a rural community health centre in Gauteng Province, South Africa: A cross-sectional study — South African Family Practice
• Hypertension Subtypes, Mortality Risk, and Differential Effects Between Two Hypertension Guidelines — Frontiers in Medicine
• The Evolution of Hypertension Guidelines Over the Last 20+ Years: A Comprehensive Review — Cureus
• Impact of ethnic-specific guidelines for anti-hypertensive prescribing in primary care in England: a longitudinal study — BMC Health Services Research
• Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report — JAMA Network Open
• Variation in hypertension clinical practice guidelines: a global comparison — BMC Medicine
• Amlodipine monotherapy vs. amlodipine–ARB combination therapy as first-line treatment for primary hypertension: a systematic review and meta-analysis — Frontiers in Cardiovascular Medicine
• Impact of the 2017 ACC/AHA hypertension guidelines on antihypertensive prescribing in the United States: real-world evidence from a nationally representative population — Frontiers in Pharmacology
• Provider Adherence to National Guidelines for Managing Hypertension in African Americans — International Journal of Hypertension
• Antihypertensive Medication Classes Used among Medicare Beneficiaries Initiating Treatment in 2007–2010 — PLoS ONE

Decision support for clinicians, not medical advice. Answers are grounded in the published literature and every claim cites its source in the interactive view.